$WLY

JOHN WILEY & SONS, INC. (WLY): Results of Operations and Financial Condition

JOHN WILEY & SONS, INC. (WLY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Wiley Reports First Quarter 2027 Results; Q1 in line with expectations and full year outlook reaffirmed Strength in Research and AI offset by prior year comparison and softness in Learning – Emerald integration ahead of schedule September 3, 2026 - Hoboken, NJ – Wiley (NYSE: WLY)

Original reporting
Published Sep 3, 2026, 1:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 1:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$WLY
Neutral
high confidence
Mentioned
$WLY
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$WLYNeutralMed
01

Why it matters

The earnings release provides fresh data on revenue mix, AI licensing growth, and cost‑saving initiatives, shaping short‑term price expectations.

02

Market read

Wiley's Q1 results and acquisition update are material for investors in publishing, education, and AI‑data sectors.

03

What to watch

The $450 M cash outlay for Emerald adds leverage; integration risks and higher net debt could pressure margins longer term.

Relevance 7/10Novelty 8/10Timing: today

Background

Wiley (NYSE: WLY) is a long‑standing scientific publisher that recently expanded into AI‑driven data services and completed the Emerald Publishing acquisition.

Company-level read

Ticker impact

$WLYNeutralHigh confidence
Context

Wiley filed an 8‑K reporting Q1 2027 results with revenue down 3% YoY, reaffirmed full‑year outlook and detailed the $450 M Emerald acquisition.

Expected impact

Potential modest upside if investors focus on AI licensing momentum and cost‑saving synergies; downside risk if revenue decline in Learning persists.

Evidence & confidence

The numbers are fresh from the SEC filing, giving traders a concrete basis to adjust positions; the reaffirmed guidance limits surprise but the acquisition narrative adds a catalyst.

Market effects

The publishing sector sees mixed signals: research revenue growth offsets learning softness, while AI licensing gains traction across publishers.

U.S. education and research stocks may react to Wiley's reaffirmed outlook and acquisition activity.

Emerald acquisition highlights consolidation trends in global academic publishing.

Counterpoint

Investors could view the revenue decline and operating loss as a warning sign, betting on a near‑term pullback.

Key entities

  • Matthew Kissner

    President and CEO of Wiley, provided commentary on the quarter.

  • Emerald Publishing

    Acquired for $450 M, adding journals and AI data assets.

Related articles

$WLYMed

JOHN WILEY & SONS, INC. (WLY): Results of Operations and Financial Condition

JOHN WILEY & SONS, INC. (WLY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991fy26q4.htm EX-99.1 Document Research and AI Momentum, Record Margins, and Cash Flow Growth Highlight Wiley's Fourth Quarter and Fiscal 2026 Results June 16, 2026 - Hoboken, NJ – Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence f

$WLYMedAI 9/10

Wiley's Q4: AI Boost, Record Margins, Cash Flow Surge

Wiley (NYSE: WLY) reported fiscal 2026 results ended April 30, 2026, including Q4 revenue of $448 million (+1% reported) and diluted EPS of $2.61 (+109%). Full-year operating income rose 25% to $277 million; adjusted operating margin hit a record 17.7%. AI revenue was $49 million (+23%) and free cash flow rose 55% to $195 million. The company returned $174 million to shareholders.

$WLYMed

Wiley Folds on Report Release

Wiley (NYSE: WLY) shares fell Thursday after the company released the Wiley Registry of Mass Spectral Data 2026. Wiley said the expanded and validated database is designed to support modern, AI-assisted lab workflows by improving identification of unknown chemical compounds and serving as a validation layer for AI-driven research.

$SMMTMed

Why is Summit Therapeutics stock surging today?

Summit Therapeutics (SMMT) stock rose 11.6% after its partner Akeso Inc. reported positive results from a Phase III study of ivonescimab. The trial met its overall survival endpoint, showing a survival advantage over pembrolizumab. Analysts remain divided, with some maintaining positive ratings. The FDA is set to review the lung cancer indication in November. The broader market also gained, supporting the rally.

$TSNHighAI 8/10

Why is Tyson Foods stock sliding today?

Tyson Foods (TSN) stock fell 6.8% premarket after cutting its fiscal 2026 adjusted operating income guidance to $1.85B-$2.05B and revenue growth forecast to 1.5%-2.0%, citing margin compression from cattle shortages and price volatility. The beef segment's expected loss widened to $775M-$625M, and CEO Donnie King noted restructuring efforts won't reduce costs until fiscal 2027. Competitor JBS also reported beef losses, indicating industry-wide challenges.